[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"detail-sidebar-cat-0-en-105":3,"doc-seo-368360-105":59,"doc-detail-368360-en":131},{"code":4,"msg":5,"data":6},0,"success",[7,13,18,23,28,33,38,43,48,51,55],{"id":8,"doc_module":4,"doc_module_name":9,"category_name":10,"show_sort_weight":11,"slug":12},1,"Document","Story & Novel",90,"story-novel",{"id":14,"doc_module":4,"doc_module_name":9,"category_name":15,"show_sort_weight":16,"slug":17},2,"Literature",80,"literature",{"id":19,"doc_module":4,"doc_module_name":9,"category_name":20,"show_sort_weight":21,"slug":22},4,"Exam",70,"exam",{"id":24,"doc_module":4,"doc_module_name":9,"category_name":25,"show_sort_weight":26,"slug":27},5,"Comic",60,"comic",{"id":29,"doc_module":4,"doc_module_name":9,"category_name":30,"show_sort_weight":31,"slug":32},6,"Technology",50,"technology",{"id":34,"doc_module":4,"doc_module_name":9,"category_name":35,"show_sort_weight":36,"slug":37},7,"Healthcare",40,"healthcare",{"id":39,"doc_module":4,"doc_module_name":9,"category_name":40,"show_sort_weight":41,"slug":42},8,"Research & Report",30,"research-report",{"id":44,"doc_module":4,"doc_module_name":9,"category_name":45,"show_sort_weight":46,"slug":47},9,"Religion & Spirituality",20,"religion-spirituality",{"id":46,"doc_module":4,"doc_module_name":9,"category_name":49,"show_sort_weight":46,"slug":50},"World Cup","world-cup",{"id":52,"doc_module":4,"doc_module_name":9,"category_name":53,"show_sort_weight":52,"slug":54},10,"Lifestyle","lifestyle",{"id":56,"doc_module":4,"doc_module_name":9,"category_name":57,"show_sort_weight":24,"slug":58},19,"General","general",{"code":4,"msg":60,"data":61},"ok",{"site_id":62,"language":63,"slug":64,"title":65,"keywords":66,"description":67,"schema_data":68,"social_meta":124,"head_meta":126,"extra_data":128,"updated_unix":130},105,"en","different-pd-l1-assays-reveal-distinct-immunobiology-and-clinical-outcomes-in-urothelial-cancer","Different PD-L1 Assays Reveal Distinct Immunobiology and Clinical Outcomes in Urothelial Cancer","","Testing PD-L1 by immunohistochemistry (IHC) is used to predict benefit from PD-1/PD-L1 immune checkpoint blockade (ICB) in urothelial cancer, but clinical trial results have been inconsistent. The study analyzes paired PD-L1 IHC data using SP142 and 22C3 assays from the phase III IMvigor130 trial and identifies discordant phenotypes. Dual-positive and SP142-only tumors show more favorable ICB outcomes with increased dendritic cell infiltration, whereas 22C3-only and double-negative profiles relate to worse survival. Findings suggest SP142 preferentially stains PD-L1+ dendritic cells, while 22C3 emphasizes tumor cell–dominant PD-L1 linked to poor outcomes.",{"@graph":69,"@context":123},[70,84,106],{"@type":71,"itemListElement":72},"BreadcrumbList",[73,77,79,82],{"item":74,"name":75,"@type":76,"position":8},"https://docshare.wps.com","Home","ListItem",{"item":78,"name":9,"@type":76,"position":14},"https://docshare.wps.com/document/",{"item":80,"name":40,"@type":76,"position":81},"https://docshare.wps.com/document/research-report/",3,{"item":83,"name":65,"@type":76,"position":19},"https://docshare.wps.com/document/different-pd-l1-assays-reveal-distinct-immunobiology-and-clinical-outcomes-in-urothelial-cancer/368360/",{"url":83,"name":65,"@type":85,"image":86,"author":91,"headline":65,"publisher":94,"fileFormat":97,"inLanguage":63,"description":67,"dateModified":98,"datePublished":99,"encodingFormat":97,"isAccessibleForFree":100,"interactionStatistic":101},"DigitalDocument",{"url":87,"@type":88,"width":89,"height":90},"https://docshare.wps.com/thumbnails/different-pd-l1-assays-reveal-distinct-immunobiology-and-clinical-outcomes-in-urothelial-cancer/368360.png","ImageObject",300,407,{"name":92,"@type":93},"Genevieve","Person",{"url":74,"name":95,"@type":96},"DocShare","Organization","application/pdf","2026-11-14","2026-09-23",true,{"@type":102,"interactionType":103,"userInteractionCount":105},"InteractionCounter",{"@type":104},"ViewAction",11,{"@type":107,"mainEntity":108},"FAQPage",[109,115,119],{"name":110,"@type":111,"acceptedAnswer":112},"What discordant PD-L1 phenotypes were identified using SP142 and 22C3 assays?","Question",{"text":113,"@type":114},"The study classifies tumors as PD-L1 positive by both assays, positive by SP142 only, positive by 22C3 only, or negative by both assays.","Answer",{"name":116,"@type":111,"acceptedAnswer":117},"How do SP142 and 22C3 results relate to clinical ICB outcomes?",{"text":118,"@type":114},"Dual-positive and SP142-only urothelial cancers are linked to more favorable ICB outcomes, whereas 22C3-only profiles are associated with worse outcomes and shorter survival.",{"name":120,"@type":111,"acceptedAnswer":121},"What biological interpretation is proposed for differences between the assays?",{"text":122,"@type":114},"SP142 may preferentially stain PD-L1–expressing dendritic cells that help orchestrate antitumor immunity, while TC-dominant PD-L1 expression reflected in 22C3 results is tied to poor ICB outcomes.","https://schema.org",{"og:url":83,"og:type":125,"og:title":65,"og:site_name":95,"og:description":67},"article",{"robots":127,"canonical":83},"index,follow",{"doc_id":129,"site_id":62},368360,1790203569,{"code":4,"msg":5,"data":132},{"doc_id":129,"user_id":133,"nickname":92,"user_avatar":134,"doc_module":4,"category_id":39,"category_name":40,"doc_title":65,"doc_description":67,"doc_content":135,"file_id":136,"file_url":137,"file_type":138,"file_size":139,"view_count":105,"is_deleted":4,"is_public":8,"is_downloadable":8,"audit_status":8,"page_count":105,"language":140,"language_code":63,"site_id":62,"html_lang":63,"table_of_contents":141,"faqs":142,"seo_title":143,"seo_description":67,"update_tm":144,"read_time":145,"preview_page_count":19,"preview_urls":146},1374391974585,"https://ap-avatar.wpscdn.com/davatar_276721f389ce27ea32af1340a28f341c","Different PD-L1 Assays Reveal Distinct Immunobiology and Clinical Outcomes in Urothelial Cancer  \nMatthew D. Galsky1, Mark Kockx2, Juliette Roels3, Roos Van Elzen2, Xiangnan Guan3, Kobe Yuen3, Deepali Rishipathak3, Jonathan F. Anker1, Sacha Gnjatic1, Sudeh Izadmehr1, Shomyseh Sanjabi3, Robert J. Johnston3, Maureen Peterson3, Hartmut Koeppen3, Justin M. David4, Saurabh Gupta4, Aristotelis Bamias5, Jose Angel Arranz6, Eiji Kikuchi7,8, Maria De Santis9,10, Ian D. Davis11,12, Patrick Williams3, Sandrine Bernhard13, Ira Mellman3, Enrique Grande14, Romain Banchereau3, and Sanjeev Mariathasan3  \n|  |  | A |  | B | S |  | T | R |  | A |  | C | T |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |\n| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |\n|  | Testing for PD-L1 expression by IHC is used to predict immune checkpoint blockade (ICB) benefits but has performed inconsistently in urothelial cancer clinical trials. Different approaches are used for PD-L1 IHC. We analyzed paired PD-L1 IHC data on urothelial cancer samples using the SP142 and 22C3 assays from the phase III IMvigor130 trial and found discordant findings summarized by four phenotypes: PD-L1 positive by both assays, PD-L1 positive by the SP142 assay only, PD-L1 positive by the 22C3 assay only, and PD-L1 negative by both assays double negative. PD-L1 positive by both assays and PD-L1 positive by the SP142 assay only urothelial cancers were associated with more favorable ICB outcomes and increased dendritic cell (DC)\u003Cbr>􀀶 |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  | infiltration. SP142 PD-L1 staining co-localized with DC-LAMP, a DC marker, whereas 22C3 staining was more diffuse. PD-L1 positive by the 22C3 assay only urothelial cancers, associated with worse outcomes, were enriched in tumor cell (TC)–dominant PDL1 expression. Multiplex IHC in an independent ICB-treated cohort confirmed that TC-dominant PD-L1 expression was associated with shorter survival. Using different PD-L1 assays, we uncovered that SP142 may preferentially stain PD-L1–expressing DCs, key to orchestrating antitumor immunity, whereas TCdominant PD-L1 expression, which underlies a subset of “PD-L1– positive” specimens, is associated with poor ICB outcomes. See related Spotlight by Karunamurthy and Davar, p. 454. |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |\n\nIntroduction  \nThe analysis of the expression of PD-L1 by IHC is among the most extensively studied pretreatment assays to determine biomarkers of response to PD-1/PD-L1 immune checkpoint blockade (ICB) in urothelial cancer and other malignancies. The association between PD-L1 protein expression and benefit from PD-1/PDL1 ICB in urothelial cancer has been largely inconsistent across clinical trials, a finding commonly attributed to (i) the dynamic nature of PD-L1 expression, (ii) the potential disconnect between PD-L1 expression assessed on archival primary tumors and the setting of treatment administered for metastatic disease, (iii)  \n1Icahn School of Medicine at Mount Sinai, New York, New York. 2CellCarta","cbCaivKwDmJg8YkR","https://ap.wps.com/l/cbCaivKwDmJg8YkR","pdf",18043817,"English","# Introduction\n## PD-L1 IHC as a biomarker for ICB response\n## Sources of inconsistency across clinical trials\n## Need to evaluate assay approaches in tumor immunology","[{\"question\":\"What discordant PD-L1 phenotypes were identified using SP142 and 22C3 assays?\",\"answer\":\"The study classifies tumors as PD-L1 positive by both assays, positive by SP142 only, positive by 22C3 only, or negative by both assays.\"},{\"question\":\"How do SP142 and 22C3 results relate to clinical ICB outcomes?\",\"answer\":\"Dual-positive and SP142-only urothelial cancers are linked to more favorable ICB outcomes, whereas 22C3-only profiles are associated with worse outcomes and shorter survival.\"},{\"question\":\"What biological interpretation is proposed for differences between the assays?\",\"answer\":\"SP142 may preferentially stain PD-L1–expressing dendritic cells that help orchestrate antitumor immunity, while TC-dominant PD-L1 expression reflected in 22C3 results is tied to poor ICB outcomes.\"}]","Different PD-L1 Assays Reveal Distinct Immunobiology and Clinical Outcomes in Urothelial Cancer | PDF",1790176520,28,[147,151,155,159],{"page_no":8,"url":148,"width":149,"height":150},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/ffa235265b8342645eb1184e32ad4899.webp",983,1315,{"page_no":14,"url":152,"width":153,"height":154},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/3622743332e836ef79ddce799b1920be.webp",982,1314,{"page_no":81,"url":156,"width":157,"height":158},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/a195c74a79dbcc85c352cd905f5c11f9.webp",981,1312,{"page_no":19,"url":160,"width":161,"height":162},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/a9ee02887afc7a985a1f344d8e8cc229.webp",980,1311]